Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Vir Biotechnology (Nasdaq: VIR) will release its fourth-quarter and full-year financial results for 2020 on February 25, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vir Biotechnology (Nasdaq: VIR) will release its fourth-quarter and full-year financial results for 2020 on February 25, 2021. The corporate update is set to follow after market close and will be available on the company’s website under the Investors section.
Vir is focused on treating serious infectious diseases through innovative immunology technologies and has a pipeline addressing COVID-19, hepatitis B, influenza A, and HIV.
Positive
- Pipeline includes candidates for COVID-19, hepatitis B, influenza A, and HIV.
Negative
- None.
Details
News Market Reaction – VIR
The recorded move for VIR in the trading session of this news was -3.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021.
The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.